Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist
Overview of attention for article published in Molecular Cancer Therapeutics, November 2012
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (85th percentile)
-
Good Attention Score compared to outputs of the same age and source (74th percentile)
Readers on
- mendeley
- 47 Mendeley